Page last updated: 2024-09-02

fingolimod and sew2871

fingolimod has been researched along with sew2871 in 3 studies

Compound Research Comparison

Studies (fingolimod)	Trials (fingolimod)	Recent Studies (post-2010) (fingolimod)	Studies (sew2871)	Trials (sew2871)	Recent Studies (post-2010) (sew2871)
65	0	51	95	0	57

Protein Interaction Comparison

Protein	Taxonomy	fingolimod (IC50)	sew2871 (IC50)
Sphingosine 1-phosphate receptor 1	Homo sapiens (human)		0.037
Sphingosine 1-phosphate receptor 5	Homo sapiens (human)		4.6

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bergstrom, J; Card, D; Chrebet, G; Ferrer, M; Hajdu, R; Hale, JJ; Hodder, P; Keohane, CA; Lynch, CL; Mandala, S; Milligan, JA; Mills, SG; Neway, W; Parent, SA; Rosen, H; Rosenbach, MJ; Shei, GJ; Strulovici, B	1
Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X	1
Camp, SM; Garcia, JGN; Marciniak, A; Polt, R	1

Reviews

1 review(s) available for fingolimod and sew2871

Article	Year
An update on sphingosine-1-phosphate receptor 1 modulators. Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Autoimmune Diseases; Biological Availability; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oxadiazoles; Receptors, Lysosphingolipid; Sphingolipids	2018

Other Studies

2 other study(ies) available for fingolimod and sew2871

Article	Year
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. Journal of medicinal chemistry, 2004, Dec-30, Volume: 47, Issue:27 Topics: Administration, Oral; Animals; Azetidines; Biological Availability; CHO Cells; Cricetinae; Dogs; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Lymphocytes; Macaca mulatta; Mice; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship	2004
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity. Bioorganic & medicinal chemistry letters, 2012, Jan-01, Volume: 22, Issue:1 Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship	2012

Article

Year

A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.

Journal of medicinal chemistry, 2004, Dec-30, Volume: 47, Issue:27

Topics: Administration, Oral; Animals; Azetidines; Biological Availability; CHO Cells; Cricetinae; Dogs; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Lymphocytes; Macaca mulatta; Mice; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship

2004

Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.

Bioorganic & medicinal chemistry letters, 2012, Jan-01, Volume: 22, Issue:1

Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship

2012